Actively Recruiting
Phase IbIIa Study of IMC-003 Injection Added to Background Therapy for Pulmonary Arterial Hypertension in Adults
Led by ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. · Updated on 2026-07-22
120
Participants Needed
29
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase IbIIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of IMC-003 injection in adults with pulmonary arterial hypertension PAH who are already receiving background therapy. The trial focuses on patients with WHO Group 1 PAH, including several subtypes such as idiopathic, heritable, and drug-induced PAH. Participants must have symptomatic PAH with specific functional classifications and hemodynamic criteria confirmed by right heart catheterization. Participants will be randomly assigned to receive either IMC-003 or a placebo, injected eight times every three weeks while continuing their stable background PAH treatment. Background therapy includes approved drugs such as endothelin receptor antagonists, PDE-5 inhibitors, sGC stimulators, and prostacyclin analogs. The study is double-blinded and parallel in design, and treatment will last for 24 weeks in both phases of the trial. During the study, participants will undergo various assessments including heart MRI, 6-minute walk distance tests, and blood tests measuring NT-proBNP and other hemodynamic parameters. Researchers will monitor safety, disease progression, and treatment effects throughout the 24-week treatment period. The study also includes ongoing evaluation of symptoms, functional classification, and laboratory markers to understand the impact of IMC-003 in this patient population.
CONDITIONS
Brief Title
A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
Research Team
X
Xiaojun Zhou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here